We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Assay Detects Fish Trematode DNA in Human Stools

By LabMedica International staff writers
Posted on 13 Jul 2017
Amphimeriasis is a fish-borne disease caused by the liver fluke Amphimerus spp. that has recently been reported as endemic in the tropical Pacific side of Ecuador with a high prevalence in humans and domestic animals.

The diagnosis of Amphimeriasis is based on the stool examination to identify parasite eggs, but it lacks sensitivity. Additionally, the morphology of the eggs may be confounded with other liver and intestinal flukes and no immunological or molecular methods have been developed to date.

Scientists at the Universidad Central del Ecuador (Quito, Ecuador) and their colleagues obtained human stool samples from indigenous communities during February 2016. The samples were processed for parasitological screening under light microscopy by direct examination, simple sedimentation, formalin-ether concentration and Kato-Katz techniques. After parasitological screening, a total of 44 stool samples were selected, including 25 (56.81%) that were positive for Amphimerus sp. eggs-by one or more parasitological methods-and 19 (43.18%) negative samples.

DNA extraction was performed using the Mini Stool DNA Extraction kit. To determine the specificity of polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) assays to amplify only Amphimerus sp. DNA, a total of 16 DNA samples from several helminths, including trematodes, cestodes, nematodes and protozoa were used. DNA was measured using a Nanodrop ND-100 spectrophotometer. The LAMP assay was called LAMPhimerus.

The team obtained from the total of 25 parasitologically positive stool samples, 9/25 (36%) and 18/25 (72%) positive results when they applied LAMPhimerus for 60 min and 120 min, respectively. Additionally, positive results included 5/19 (26.3%) samples that were negative in all previously applied parasitological tests. Of the 11 that were simultaneously positive on three parasitological tests 82% were also positive on the LAMP assay; only the two samples, with the same very low egg count, were negative on the LAMP assay.

The authors have developed, for the first time, a LAMP assay (namely, LAMPhimerus) for the sensitive and specific detection of Amphimerus sp. DNA in human stool samples. After further studies for validation, the method could be readily adapted for effective field diagnosis and disease surveillance in amphimeriasis-endemic areas. The study was published on June 19, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Universidad Central del Ecuador


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.